Plasma components, such as fresh frozen plasma (FFP), fresh plasma, frozen plasma, and cryoprecipitates, are commonly used for the correction of bleeding due to the deficiency of blood coagulation factors. Furthermore, blood coagulation factors and plasma proteins are components of plasma that enable the manufacture of plasma derivatives, including factor VIII concentrates, factor IX concentrates, immunoglobulin, and albumin. In this paper, we discuss the current domestic status of plasma use and the related insurance policy of the Health Insurance Review & Assessment Service (HIRA), which ensures health insurance for the entire South Korean nation. This in turn will aid in developing a proposal for the proper use of plasma components.